APA (7th ed.) Citation

E, F., HC, G., MC, R., C, N., A, H., FT, B., & LS, L. (2022). Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trial. Diabetes, obesity & metabolism, 24(9), 1753. https://doi.org/10.1111/dom.14760

Chicago Style (17th ed.) Citation

E, Franek, Gerstein HC, Riddle MC, Nicolay C, Hickey A, Botros FT, and Loo LS. "Efficacy and Safety Outcomes of Dulaglutide by Baseline HbA1c: A Post Hoc Analysis of the REWIND Trial." Diabetes, Obesity & Metabolism 24, no. 9 (2022): 1753. https://doi.org/10.1111/dom.14760.

MLA (9th ed.) Citation

E, Franek, et al. "Efficacy and Safety Outcomes of Dulaglutide by Baseline HbA1c: A Post Hoc Analysis of the REWIND Trial." Diabetes, Obesity & Metabolism, vol. 24, no. 9, 2022, p. 1753, https://doi.org/10.1111/dom.14760.